Intra- and extracellular activities of dicloxacillin and linezolid against a clinical Staphylococcus aureus strain with a small-colony-variant phenotype in an in vitro model of THP-1 macrophages and an in vivo mouse peritonitis model

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1443-1452

  Sandberg, Anne ^a   Lemaire, Sandrine ^b   Van Bambeke, Françoise ^b   Tulkens, Paul M ^b   Hughes, Diarmaid ^c   Von Eiff, Christof ^d,e   Frimodt Møller, Niels ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOXACILLIN; LINEZOLID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELL LINE; GENETIC VARIABILITY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PATHOGENESIS; PERITONITIS; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SMALL COLONY VARIANT PHENOTYPE; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; DICLOXACILLIN; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; HUMANS; MACROPHAGES; MICE; OXAZOLIDINONES; PERITONITIS; PHENOTYPE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 79953180561     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00205-10     Document Type: Article

References (57)

1. Bamberger, D. M., and S. E. Boyd. 2005. Management of Staphylococcus aureus infections. Am. Fam. Physician 72:2474-2481.
2. Barcia-Macay, M., S. Lemaire, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:1177-1184.
3. Barcia-Macay, M., C. Seral, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50:841-851.
4. Bates, D. M., et al. 2003. Staphylococcus aureus menD and hemB mutants are as infective as the parent strains, but the menadione biosynthetic mutant persists within the kidney. J. Infect. Dis. 187:1654-1661.
5. Baudoux, P., et al. 2007. Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J. Antimicrob. Chemother. 59:246-253.
6. Besier, S., A. Ludwig, K. Ohlsen, V. Brade, and T. A. Wichelhaus. 2007. Molecular analysis of the thymidine-auxotrophic small colony variant phenotype of Staphylococcus aureus. Int. J. Med. Microbiol. 297:217-225.
7. Besier, S., et al. 2007. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J. Clin. Microbiol. 45:168-172.
8. Besier, S., et al. 2008. The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 52:2183-2189.
9. Brouillette, E., G. Grondin, L. Shkreta, P. Lacasse, and B. G. Talbot. 2003. In vivo and in vitro demonstration that Staphylococcus aureus is an intracellular pathogen in the presence or absence of fibronectin-binding proteins. Microb. Pathog. 35:159-168.
10. Brouillette, E., A. Martinez, B. J. Boyll, N. E. Allen, and F. Malouin. 2004. Persistence of a Staphylococcus aureus small-colony variant under antibiotic pressure in vivo. FEMS Immunol. Med. Microbiol. 41:35-41.
11. Carryn, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2002. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob. Agents Chemother. 46:2095-2103.
12. Chang, F. Y., et al. 2003. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82:333-339.
13. Chatterjee, I., et al. 2008. In vivo mutations of thymidylate synthase (encoded by thyA) are responsible for thymidine dependency in clinical small-colony variants of Staphylococcus aureus. J. Bacteriol. 190:834-842.
14. Ciampolini, J., and K. G. Harding. 2000. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? Postgrad. Med. J. 76:479-483.
15. Clement, S., et al. 2005. Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosinusitis. J. Infect. Dis. 192:1023-1028.
16. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement (M100-S15). Clinical and Laboratory Standards Institute, Wayne, PA.
17. Frimodt-Moller, N. 1993. The mouse peritonitis model: present and future use. J. Antimicrob. Chemother. 31(Suppl. D):55-60.
18. Grayson, M. L. 2006. The treatment triangle for staphylococcal infections. N. Engl. J. Med. 355:724-727.
19. Gresham, H. D., et al. 2000. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J. Immunol. 164:3713-3722. (Pubitemid 30169827)
20. Hess, D. J., M. J. Henry-Stanley, E. A. Erickson, and C. L. Wells. 2003. Intracellular survival of Staphylococcus aureus within cultured enterocytes. J. Surg. Res. 114:42-49.
21. Jensen, A. G., et al. 2002. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch. Intern. Med. 162:25-32.
22. Johnson, L. B., M. O. Almoujahed, K. Ilg, L. Maolood, and R. Khatib. 2003. Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand. J. Infect. Dis. 35:782-789.
23. Jonsson, I. M., et al. 2003. Virulence of a hemB mutant displaying the phenotype of a Staphylococcus aureus small colony variant in a murine model of septic arthritis. Microb. Pathog. 34:73-79.
24. Kahl, B., et al. 1998. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J. Infect. Dis. 177:1023-1029.
25. Lannergard, J., et al. 2008. Identification of the genetic basis for clinical menadione-auxotrophic small-colony variant isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 52:4017-4022.
26. Lemaire, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2005. Activity of three beta-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J. Antimicrob. Chemother. 55:897-904.
27. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
28. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339:520-532.
29. Lowy, F. D. 2000. Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol. 8:341-343.
30. Mempel, M., et al. 2002. Invasion of human keratinocytes by Staphylococcus aureus and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death. Br. J. Dermatol. 146:943-951.
31. Miller, M. H., M. A. Wexler, and N. H. Steigbigel. 1978. Single and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutants. Antimicrob. Agents Chemother. 14:336-343.
32. Murchan, S., et al. 2003. Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. J. Clin. Microbiol. 41:1574-1585.
33. Nguyen, H. A., et al. 2009. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. Antimicrob. Agents Chemother. 53:1434-1442.
34. Pelletier, L. L., Jr., M. Richardson, and M. Feist. 1979. Virulent gentamicin-induced small colony variants of Staphylococcus aureus. J. Lab. Clin. Med. 94:324-334.
35. Proctor, R. A., et al. 1998. Staphylococcal small colony variants have novel mechanisms for antibiotic resistance. Clin. Infect. Dis. 27(Suppl. 1):S68-S74.
36. Proctor, R. A., P. van Langevelde, M. Kristjansson, J. N. Maslow, and R. D. Arbeit. 1995. Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus. Clin. Infect. Dis. 20:95-102.
37. Proctor, R. A., et al. 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat. Rev. Microbiol. 4:295-305.
38. Quie, P. G. 1969. Microcolonies (G-variants) of Staphylococcus aureus. Yale J. Biol. Med. 41:394-403.
39. Roder, B. L., et al. 1999. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch. Intern. Med. 159:462-469.
40. Sadowska, B., et al. 2002. Characteristics of Staphylococcus aureus, isolated from airways of cystic fibrosis patients, and their small colony variants. FEMS Immunol. Med. Microbiol. 32:191-197.
41. Sandberg, A., J. H. Hessler, R. L. Skov, J. Blom, and N. Frimodt-Moller. 2009. Intracellular activity of antibiotics against Staphylococcus aureus in the mouse peritonitis model. Antimicrob. Agents Chemother. 53:1874-1883.
42. Schmidt-Ioanas, M., A. de Roux, and H. Lode. 2005. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Curr. Opin. Crit. Care 11:481-486.
43. Schroder, A., R. Kland, A. Peschel, C. von Eiff, and M. Aepfelbacher. 2006. Live cell imaging of phagosome maturation in Staphylococcus aureus infected human endothelial cells: small colony variants are able to survive in lysosomes. Med. Microbiol. Immunol. 195:185-194.
44. Seral, C., F. Van Bambeke, and P. M. Tulkens. 2003. Quantitative analysis of gentamicin,azithromycin,telithromycin,ciprofloxacin,moxifloxacin, andoritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob. Agents Chemother. 47:2283-2292.
45. Sifri, C. D., A. Baresch-Bernal, S. B. Calderwood, and C. von Eiff. 2006. Virulence of Staphylococcus aureus small colony variants in the Caenorhabditis elegans infection model. Infect. Immun. 74:1091-1096.
46. Stalker, D. J., and G. L. Jungbluth. 2003. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin. Pharmacokinet. 42:1129-1140.
47. Tsuchiya, S., et al. 1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer 26:171-176. (Pubitemid 10086416)
48. Tulkens, P. M. 1991. Intracellular distribution and activity of antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 10:100-106.
49. Van Bambeke, F., M. Barcia-Macay, S. Lemaire, and P. M. Tulkens. 2006. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr. Opin. Drug Discov. Devel. 9:218-230.
50. Vaudaux, P., et al. 2002. Increased expression of clumping factor and fibronectin- binding proteins by hemB mutants of Staphylococcus aureus expressing small colony variant phenotypes. Infect. Immun. 70:5428-5437.
51. Vesga, O., et al. 1996. Staphylococcus aureus small colony variants are induced by the endothelial cell intracellular milieu. J. Infect. Dis. 173:739-742.
52. von Eiff, C. 2008. Staphylococcus aureus small colony variants: a challenge to microbiologists and clinicians. Int. J. Antimicrob. Agents 31:507-510.
53. von Eiff, C., et al. 1997. Recovery of small colony variants of Staphylococcus aureus following gentamicin bead placement for osteomyelitis. Clin. Infect. Dis. 25:1250-1251.
54. von Eiff, C., et al. 1997. A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly. J. Bacteriol. 179:4706-4712.
55. von Eiff, C., G. Peters, and K. Becker. 2006. The small colony variant (SCV) concept - the role of staphylococcal SCVs in persistent infections. Injury 37(Suppl. 2):S26-S33.
56. von Eiff, C., R. A. Proctor, and G. Peters. 2000. Staphylococcus aureus small colony variants: formation and clinical impact. Int. J. Clin. Pract. Suppl. 2000:44-49.
57. Zander, J., et al. 2008. Influence of dTMP on the phenotypic appearance and intracellular persistence of Staphylococcus aureus. Infect. Immun. 76:1333-1339.